Tonix Pharmaceuticals Holding Corp. (TNXP)
13.93
-0.17
(-1.21%)
USD |
NASDAQ |
Sep 01, 14:54
Tonix Pharmaceuticals Total Long Term Debt (Quarterly) : 1.022M for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.022M |
| March 31, 2026 | 1.128M |
| December 31, 2025 | 1.184M |
| September 30, 2025 | 0.266M |
| June 30, 2025 | 0.297M |
| March 31, 2025 | 0.328M |
| December 31, 2024 | 5.025M |
| September 30, 2024 | 5.597M |
| June 30, 2024 | 6.161M |
| March 31, 2024 | 6.721M |
| December 31, 2023 | 7.193M |
| September 30, 2023 | 0.716M |
| June 30, 2023 | 0.831M |
| March 31, 2023 | 0.588M |
| December 31, 2022 | 0.328M |
| September 30, 2022 | 0.382M |
| June 30, 2022 | 0.474M |
| March 31, 2022 | 0.405M |
| December 31, 2021 | 0.467M |
| September 30, 2021 | 0.53M |
| June 30, 2021 | 0.591M |
| March 31, 2021 | 0.577M |
| December 31, 2020 | 0.716M |
| September 30, 2020 | 0.671M |
| June 30, 2020 | 0.095M |
| Date | Value |
|---|---|
| March 31, 2020 | 0.025M |
| December 31, 2019 | 0.006M |
| September 30, 2019 | 0.051M |
| June 30, 2019 | 0.139M |
| March 31, 2019 | 0.20M |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| Exelixis, Inc. | 165.93M |
| Inovio Pharmaceuticals, Inc. | 5.103M |
| Heron Therapeutics, Inc. | 148.15M |
| ACADIA Pharmaceuticals, Inc. | 59.55M |
| Alnylam Pharmaceuticals, Inc. | 2.942B |